The Magnificent Seven: Seven good publications in infectious disease
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:68-70. doi: 10.37201/req/s01.16.2023. Epub 2023 Nov 24.ABSTRACTThe world of infectious diseases, for various reasons, before and after the COVID-19 pandemic, capture the attention of the scientific community, either due to the epidemiological data of various microbial agents that are emerging, due to the implementation with successful results of new diagnostic strategies or due to the appearance of new therapeutic options, which encourage healthcare workers to continue on the front line. Topics such as antimicrobial resistance, S. aureus bacteremia, clostridioides difficile, short tre...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: O Algara L E Franco J M Garc ía-Lechuz Source Type: research
Introduction to XIII Updating Course of Antimicrobials and Infectious Diseases
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:1. doi: 10.37201/req/s01.00.2023. Epub 2023 Nov 24.NO ABSTRACTPMID:37997860 | DOI:10.37201/req/s01.00.2023 (Source: Revista Espanola de Quimioterapia)
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: F J Candel Source Type: research
Enterococcus spp. and Streptococcus spp. bloodstream infections: epidemiology and therapeutic approach
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:2-4. doi: 10.37201/req/s01.01.2023. Epub 2023 Nov 24.ABSTRACTStreptococcus spp. and Enterococcus spp. are frequent etiologies of bloodstream infection and endocarditis. In recent years, the incidence of Enterococcus spp. has been increasing, especially with nosocomial involvement, and with a high mortality rate. In this entity, the risk of endocarditis and its relationship with colorectal neoplastic pathology remains to be clarified, in order to establish indications for echocardiography and colonoscopy. In the case of Streptococcus spp., the risk of endocarditis depends on the specie...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: R Blanes Hern ández M Blanes Juli á Source Type: research
The microbiology of sepsis is more than the application of new technologies in diagnosis
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:5-8. doi: 10.37201/req/s01.02.2023. Epub 2023 Nov 24.ABSTRACTAdequate and rapid microbiological diagnosis of sepsis is essential for correct treatment, having a direct impact on patient prognosis. Clinical Microbiology Services must adapt fast circuits that allow prioritizing and individualizing the diagnosis of these patients. The measures adopted should not be based solely on the incorporation of new technologies but, to a large extent, on ensuring accurately collection and processing of samples, avoiding unnecessary losses of time in processing and ensuring that the information der...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: M N Larrosa Escart ín M A Mart ínez-López P Nadal-Bar ón Source Type: research
Nosocomial pneumonia: Current etiology and impact on antimicrobial therapy
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:9-14. doi: 10.37201/req/s01.03.2023. Epub 2023 Nov 24.ABSTRACTNosocomial pneumonia is an infection with high clinical impact and high morbimortality in which Pseudomonas aeruginosa plays a priority role, especially in the critically ill patient. Conventional antipseudomonal treatments, historically considered as standard, are currently facing important challenges due to the increase of antimicrobial resistance. In recent years, new antimicrobials have been developed with attractive sensitivity profiles and remarkable efficacy in clinical scenarios of nosocomial pneumonia including bac...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: J J Gamazo F J Candel J Gonz ález Del Castillo Source Type: research
Risk of severe COVID in solid organ transplant recipient
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:15-17. doi: 10.37201/req/s01.04.2023. Epub 2023 Nov 24.ABSTRACTDespite the fact that COVID is today not a life-threat for the general population, recipients of solid organ transplantation should be viewed as a high risk group for severe COVID. Repetitive doses of SARS-CoV-2 vaccine still fail to protect SOT recipients from infection, disease or even death caused by COVID. A more frequent need for medical care may initially place these patients at greater chances of SARS-CoV-2 infection. Immunosuppression after engrafting and underlying medical conditions that led to the practice of SO...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: P Barreiro F J Candel M M Carretero J San Rom án Source Type: research
Therapeutic strategy in the transplanted patient
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:18-21. doi: 10.37201/req/s01.05.2023. Epub 2023 Nov 24.ABSTRACTThe SARS-CoV-2 infection prognosis has dramatically changed as a result of population vaccination and the surge of omicron. However, there are still specific populations at risk of progression to severe diseases that require hospitalization or even at risk of death. The kidney transplant population is one of them. Consequently, when compatible symptoms appear, an early diagnosis should be sought in order to start specific antiviral treatment as soon as possible to avoid clinical deterioration of the patient. Antivirals hav...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: M J N úñez-Orantos A Juli án-Jiménez F J Candel J Gonz ález Del Castillo Source Type: research
SARS-CoV-2 infection in solid organ transplant recipients: Experience with molnupiravir
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:22-24. doi: 10.37201/req/s01.06.2023. Epub 2023 Nov 24.ABSTRACTSolid organ transplant recipients (SOTR) constitute one of the groups at highest risk for the development of severe COVID-19. However, evidence on the effectiveness of treatments for SARS-CoV-2 infection in this group of patients is scarce. Molnupiravir is an orally administered antiviral drug that has demonstrated effectiveness in reducing the risk of progression to severe COVID-19 in high-risk outpatients, mainly in the unvaccinated population. Although its effectiveness is lower than that of other antivirals, on many oc...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: M Villamar ín O Len Source Type: research
Clinical experience in the treatment of COVID-19 with monoclonal antibodies in solid organ transplant recipients
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:25-28. doi: 10.37201/req/s01.07.2023. Epub 2023 Nov 24.ABSTRACTSolid organ transplant (SOT) recipients are at high risk for complications from coronavirus disease 2019 (COVID-19). SOT recipients mount lower immunological responses to vaccines than general population and are at high risk for breakthrough COVID-19 infections. Passive immunotherapy in the form of anti-Spike monoclonal antibodies (MoAbs) may be an alternative for the prophylaxis and treatment of COVID-19 in these patients. SARS-CoV-2 has evolved by accumulating resistance mutations that have escaped the neutralizing actio...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: E M úñez-Rubio J Calder ón-Parra A Guti érrez-Villanueva A Fern ández-Cruz A Ramos-Mart ínez Source Type: research
Mpox global outbreak: update in epidemiology, clinical spectrum and considerations in prevention and treatment
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:29-32. doi: 10.37201/req/s01.08.2023. Epub 2023 Nov 24.ABSTRACTMpox is the most prevalent Orthopoxvirus infection in humans. Several clinical characteristics of mpox distinguish this disease from other rash illnesses. Complications are not uncommon. New therapeutics and vaccines are likely to change the course of the disease, especially in immunocompromised individuals. Clinicians must ensure that access to treatment and prevention measures are guaranteed especially in this particular population. This review exposes the epidemiology, clinical spectrum and updated considerations in tre...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: S Fern ández-Castelao E Orviz Source Type: research
Group A Streptococcus invasive infection in children: Epidemiologic changes and implications
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:33-36. doi: 10.37201/req/s01.09.2023. Epub 2023 Nov 24.ABSTRACTGroup A Streptococcus (GAS) can cause a broad array of clinical manifestations and complications. Recently, in post COVID-19 postpandemic months, there has been an increased incidence and severity of invasive infections in the pediatric age group in Spain and other European countries with high morbidity, affecting mostly to young children, associated with seasonal peaks in incidence of viral respiratory pathogens. The increased in incidence and severity has not been associated with predominant GAS strains, but rather to th...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: J T Ramos Amador A Berzosa S ánchez M Ill án Ramos Source Type: research
Current approach to skin and soft tissue infections. Thinking about continuity of care
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:37-45. doi: 10.37201/req/s01.10.2023. Epub 2023 Nov 24.ABSTRACTSkin and soft tissue infections are a common reason for patients seeking inpatient and outpatient medical care. Surgery is an essential part of managing in many episodes. Careful evaluation of antibiotic therapy could help clinicians in early identification to patients with treatment failure and to consider an alternative approach or a new surgical revision in "focus control". With the arrival of new drugs, there is a need to refine the appropriate drug's decision-making. Drugs with a long half-life (long-acting lipoglycop...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: R Blanes Hern ández M Rodr íguez Pérez J Fern ández Navarro M Salavert Llet í Source Type: research
Treatment guidelines for multidrug-resistant Gram-negative microorganisms
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:46-51. doi: 10.37201/req/s01.11.2023. Epub 2023 Nov 24.ABSTRACTIn recent years, new antimicrobials have been introduced in therapeutics, including new beta-lactam-beta-lactamase inhibitor combinations and cefiderocol in response to therapeutic needs in the face of increasing resistance. There are also different treatment guidelines for infections caused by these microorganisms that have been approved by different professional societies, including those of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Disease Society of America (IDSA) an...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: R Cant ón P Ruiz-Garbajosa Source Type: research
Post-CART-T Cell Infection: Etiology, pathogenesis, and therapeutic approaches
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:52-53. doi: 10.37201/req/s01.12.2023. Epub 2023 Nov 24.ABSTRACTChimeric antigen receptor (CAR) T cell therapy targeting CD-19 has revolutionized the treatment of refractory B-cell malignancies. However, patients undergoing this therapy face an increased risk of infections due to compromised immune function, lymphodepleting chemotherapy, hospitalization, and therapy-related complications such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome. Patients with systemic corticosteroid use, low immunoglobulin levels, and severe CRS, are at higher r...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: N Garc ía-Poutón O Peyrony M Chumbita F Aiello P Monzo A Gallardo-Pizarro C Garcia-Vidal Source Type: research
Present and future of resistance in Pseudomonas aeruginosa: implications for treatment
Rev Esp Quimioter. 2023 Nov;36 Suppl 1:54-58. doi: 10.37201/req/s01.13.2023. Epub 2023 Nov 24.ABSTRACTPseudomonas aeruginosa is a pathogen that has a high propensity to develop antibiotic resistance, and the emergence of multidrug-resistant strains is a major concern for global health. The mortality rate associated with infections caused by this microorganism is significant, especially those caused by multidrug-resistant strains. The antibiotics used to treat these infections include quinolones, aminoglycosides, colistin, and β-lactams. However, novel combinations of β-lactams-β-lactamase inhibitors and cefiderocol offe...
Source: Revista Espanola de Quimioterapia - November 24, 2023 Category: Drugs & Pharmacology Authors: M Pina-S ánchez M Rua J L Del Pozo Source Type: research
